Cell Therapy Enforcement Discretion Ending, But US FDA Still Faces Challenge Going After Bad Actors

 
• By Sarah Karlin-Smith
  
Basketball on court
Stem cell experts say the ball is now in the FDA’s court to remove bad actors from the market. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies